2025年5月9日 银河观点集萃 责任编辑 周颖 ☎：010-80927635 网:zhouying_yj@chinastock.com.cn 分析师登记编码：S0130511090001 要闻 中华人民共和国和俄罗斯联邦发布关于全球 战略稳定的联合声明 每日晨报 www.chinastock.com.cn 证券研究报告 请务必阅读正文最后的中国银河证券股份有限公司免责声明 ● 宏观:降息需要更长等待,联储内部可能分为两派。目前,我们认为第一种情 况出现的概率更高,即美联储仍可以在下半年开启降息,但 7月出现首次降息 的概率正在走弱。这一方面是由于关税谈判进展仍然缓慢,另一方面,美国经 济增长惯性的延续叠加私人部门存货对通胀上升和劳动市场下行造成缓冲,7 月美联储也未必有足够数据判断是否应该降息。不过,我们仍认为 2025年的 通胀中枢并不会明显高于 3.0%-3.5%的范围,也并不会影响长期通胀中枢,因 此货币政策并不会持续紧绷,美联储依然可以在年内降息 50-75BP。 策略:一揽子金融政策稳市场稳预期。A 股市场投资展望：一系列政策持续加 0 码的环境下,A 股市场长期稳健运行具备更为坚实的基础。继 4 ...

Group 1 - The company reported a revenue of 782 million yuan for 2024, representing a year-on-year growth of 33.33%, with a net profit attributable to the parent company of 83 million yuan, up 20.82% year-on-year [1] - In Q1 2025, the company achieved a revenue of 189 million yuan, a year-on-year increase of 22.39%, and a net profit attributable to the parent company of 29 million yuan, up 72.98% year-on-year [1] - The core business of chromatography fillers and media generated a revenue of 451 million yuan in 2024, with a year-on-year growth of 10.20% [2] Group 2 - The newly added chromatography analysis instruments and accessories contributed a revenue of 154 million yuan, primarily from the consolidation of the acquired company Fuli Instruments [2] - The market for chromatography fillers is expanding, with a current domestic market penetration rate of only about 10%, indicating significant potential for domestic substitution [3] - The company has established strategic cooperation agreements with five major clients, resulting in a sales volume of 224 million yuan, accounting for 50% of the revenue from chromatography fillers [3] Group 3 - The company is evolving into a leading domestic supplier of chromatography fillers, consumables, and instruments, driven by underlying technology [4] - Revenue projections for 2025-2027 are 977 million yuan, 1.17 billion yuan, and 1.37 billion yuan, with net profits of 134 million yuan, 203 million yuan, and 290 million yuan respectively [4] - The current stock price corresponds to a PE ratio of 67, 45, and 31 times for 2025-2027 [4]

Company Overview - Hanbang Technology is a high-tech enterprise focused on chromatography technology, providing professional separation and purification equipment, consumables, application technology services, and related technical solutions primarily for the pharmaceutical and life sciences sectors [1]. IPO Details - The company is set to launch its public offering with a total share capital of 66 million shares, of which 22 million shares will be publicly issued, representing 25% of the post-issue total share capital [1]. - The issue price is set at 22.77 yuan per share, with an earnings per share (EPS) ratio of 26.35 times, compared to the industry average of 28.04 times [1]. - The maximum subscription limit for a single account is 5,000 shares, requiring a minimum market value of 50,000 yuan in the Shanghai market for top-tier subscriptions [1]. Fundraising Allocation - The funds raised will be allocated to several projects, including: - Production project for 1,000 units of liquid chromatography series separation equipment (193.03 million yuan) - Construction of a chromatography separation equipment R&D center (271.10 million yuan) - Production project for 2,000 units of laboratory chromatography separation and purification instruments (224.76 million yuan) - Supplementing working capital (291.11 million yuan) [1]. Financial Performance - Key financial indicators for Hanbang Technology include: - Total assets for 2024 are projected at 1.32 billion yuan, a decrease from 1.35 billion yuan in 2023 and 1.40 billion yuan in 2022 [1]. - Net assets have increased to 739.63 million yuan in 2024 from 638.37 million yuan in 2023 and 566.92 million yuan in 2022 [1]. - Operating revenue is expected to reach 690.88 million yuan in 2024, up from 619.01 million yuan in 2023 and 481.79 million yuan in 2022 [1]. - Net profit attributable to shareholders is projected at 79.34 million yuan for 2024, compared to 51.50 million yuan in 2023 and 38.56 million yuan in 2022 [1]. - Basic and diluted earnings per share are both expected to be 1.20 yuan in 2024, up from 0.78 yuan in 2023 and 0.62 yuan in 2022 [1]. - The weighted average return on equity is projected at 11.51% for 2024, an increase from 8.55% in 2023 and 9.86% in 2022 [1]. - Net cash flow from operating activities is expected to be 129.88 million yuan in 2024, compared to 113.33 million yuan in 2023 and 19.84 million yuan in 2022 [1]. - R&D investment is projected at 41.85 million yuan in 2024, representing 6.06% of operating revenue, consistent with previous years [1].

Core Viewpoint - The company, Suzhou Nanwei Technology Co., Ltd., focuses on the research, production, and sales of high-performance nano-microsphere materials, aiming to become a leading brand in the microsphere industry and break the long-standing foreign monopoly in this field [7][28]. Company Overview - The company specializes in high-performance nano-microsphere materials for applications in biomedicine, flat panel displays, analytical testing, and in vitro diagnostics [7][9]. - It has developed proprietary technologies for precise control over microsphere size, morphology, and surface properties, enabling customized production [8][28]. Business Model - The company operates a complete procurement, production, sales, and R&D system, adapting its business model based on market conditions and customer needs [10][11]. - It employs a direct sales model, engaging with clients from the early stages of product development to provide tailored purification solutions [14][31]. Industry Situation - The biopharmaceutical separation and purification industry is critical, with chromatography technology being the primary method for achieving high purity and yield in biopharmaceutical production [17][20]. - The global biopharmaceutical market is projected to grow significantly, with a compound annual growth rate (CAGR) of 12.20% from 2020 to 2025, driven by advancements in monoclonal antibody products [18][19]. Market Dynamics - The Chinese biopharmaceutical market is expected to reach RMB 811.6 billion by 2025, with a CAGR of 18.6% from 2020 to 2025, indicating strong growth potential [19]. - The demand for domestic high-performance separation and purification materials is increasing due to rising production costs and the need for stable supply chains amid international uncertainties [30][32]. Technological Development - The company has established a comprehensive technology development and industrialization system for microsphere precision preparation, making it one of the few capable of large-scale production of both inorganic and organic high-performance nano-microspheres [28]. - Recent acquisitions, such as that of Fuli Instruments, enhance the company's capabilities in providing integrated analytical solutions [29]. Financial Overview - The company plans to distribute a cash dividend of RMB 0.63 per share, with total cash dividends and share repurchase amounting to RMB 86.24 million, representing 104.10% of the net profit attributable to shareholders for 2024 [4][5].

近年来，中国色谱市场正经历明显的"冰火两重天"局面：一方面，国内市场持续疲软，市场竞争日益激烈，中小企业生存承压；另一方面，国 产替代浪潮加速，头部企业融资频获突破，技术应用场景持续深化。在此背景下， ACCSI 2 0 2 5色谱新应用场景及产业生态升级发展论坛 将于 2 0 2 5年5月1 2日下午 在上海松江区富悦大酒店召开。论坛将汇聚行业领军者、顶级专家及产业链上下游代表，共同探讨中国色谱技术突围路径 与市场机遇。 点击报名参会 核心亮点抢先看 亮点一 聚焦细分市场突围，解码国产替代行业机遇 在中美关税战升级与政策强驱动下，色谱下游应用行业对降本增效、国产设备的迫切需求成为关键推力。特别是主流应用市场——制药与石化 领域成为破局关键。论坛将深度解析细分市场动态，邀请业内权威专家结合政策红利与行业痛点，探讨行业应用现状于需求，探讨国产色谱如 何从实现大市场的"国产替代"。 导读： 聚焦色谱技术，探讨国产替代机遇与产业升级路径，共话行业发展新趋势。ACCSI 2025色谱新应用场景及产业生态升级发展论坛将于2025年5月12日下午 在上海松江区富悦大酒店召开。 特别提示 微信公众号机制调整，请点击顶部"仪 ...